Book contents
- 50 Big Debates in Gynecologic Oncology
- 50 Big Debates in Gynecologic Oncology
- Copyright page
- Contents
- Contributors
- Section I Perioperative Management
- Section II Screening, Prevention, and Early Diagnosis
- Section III Ovarian Cancer
- Section IV Endometrial Cancer
- Section V Cervical Cancer
- Section VI Vaginal and Vulvar Cancer
- Debate 48A Should the Subsequent Management of Patients with Vulvar Cancer and a Positive Sentinel Lymph Node be Complete Groin Lymph Node Dissection or Radiation Therapy?
- Debate 48B Should the Subsequent Management of Patients with Vulvar Cancer and a Positive Sentinel Lymph Node be Complete Groin Lymph Node Dissection or Radiation Therapy?
- Debate 49A What is the Best Treatment for Stage I Vulvar Squamous Cell Carcinoma with either a Close or Positive Surgical Margin?
- Debate 49B What is the Best Treatment for Stage I Vulvar Squamous Cell Carcinoma with either a Close or Positive Surgical Margin?
- Debate 50A Should Adjuvant Radiation be Given to Women with Single Node Positive Vulvar Cancer?
- Debate 50B Should Adjuvant Radiation Therapy be Given to Patients with Single Node Positive Vulvar Cancer?
- Debate 51A Is Pelvic Exenteration an Option for a Pelvic Recurrence of a Vulvar/Vaginal Melanoma after Previous Radiation Therapy?
- Debate 51B Is Pelvic Exenteration an Option for a Pelvic Recurrence of a Vulvar/Vaginal Melanoma after Previous Radiation Therapy?
- Index
- References
Debate 51B - Is Pelvic Exenteration an Option for a Pelvic Recurrence of a Vulvar/Vaginal Melanoma after Previous Radiation Therapy?
No
from Section VI - Vaginal and Vulvar Cancer
Published online by Cambridge University Press: 20 July 2023
Book contents
- 50 Big Debates in Gynecologic Oncology
- 50 Big Debates in Gynecologic Oncology
- Copyright page
- Contents
- Contributors
- Section I Perioperative Management
- Section II Screening, Prevention, and Early Diagnosis
- Section III Ovarian Cancer
- Section IV Endometrial Cancer
- Section V Cervical Cancer
- Section VI Vaginal and Vulvar Cancer
- Debate 48A Should the Subsequent Management of Patients with Vulvar Cancer and a Positive Sentinel Lymph Node be Complete Groin Lymph Node Dissection or Radiation Therapy?
- Debate 48B Should the Subsequent Management of Patients with Vulvar Cancer and a Positive Sentinel Lymph Node be Complete Groin Lymph Node Dissection or Radiation Therapy?
- Debate 49A What is the Best Treatment for Stage I Vulvar Squamous Cell Carcinoma with either a Close or Positive Surgical Margin?
- Debate 49B What is the Best Treatment for Stage I Vulvar Squamous Cell Carcinoma with either a Close or Positive Surgical Margin?
- Debate 50A Should Adjuvant Radiation be Given to Women with Single Node Positive Vulvar Cancer?
- Debate 50B Should Adjuvant Radiation Therapy be Given to Patients with Single Node Positive Vulvar Cancer?
- Debate 51A Is Pelvic Exenteration an Option for a Pelvic Recurrence of a Vulvar/Vaginal Melanoma after Previous Radiation Therapy?
- Debate 51B Is Pelvic Exenteration an Option for a Pelvic Recurrence of a Vulvar/Vaginal Melanoma after Previous Radiation Therapy?
- Index
- References
Summary
Patients with vulvovaginal melanoma should not be considered for pelvic exenteration except possibly as a last resort in very rare, highly select cases. Instead, these patients may be best treated with a combination of hypofractionated radiation therapy and immunotherapy.
- Type
- Chapter
- Information
- 50 Big Debates in Gynecologic Oncology , pp. 310 - 312Publisher: Cambridge University PressPrint publication year: 2023
References
Mert, I, et al. Vulvar/vaginal melanoma: an updated Surveillance Epidemiology and End Results Database review, comparison with cutaneous melanoma and significance of racial disparities. Int J Gynecol Cancer 2013;23:1118–1125.CrossRefGoogle ScholarPubMed
Schiavone, MB, et al. Combined immunotherapy and radiation for treatment of mucosal melanomas of the lower genital tract. Gynecol Oncol Rep 2016;16:42–46.CrossRefGoogle ScholarPubMed
Salama, AKS, et al. Ipilimumab and radiation in patients with high risk resected or regionally advanced melanoma. Clin Cancer Res 2021;27(5):1287–1295.CrossRefGoogle ScholarPubMed
National Comprehensive Cancer Network. Melanoma: cutaneous (Version 1.2021). Available from: www.nccn.org/professionals/physician_gls/pdf/cutaneous_melanoma.pdfGoogle Scholar
Dummer, R, et al. Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicenter, open-label, randomized, phase 3 trial. Lancet Oncol 2018;19:1315–1327.CrossRefGoogle ScholarPubMed
Wasif, N, et al. Does metastatectomy improve survival in patients with stage IV melanoma? A cancer registry analysis of outcomes. J Surg Oncol 2011;104:111–115.CrossRefGoogle Scholar